Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • بيانات النشر:
      Elsevier
    • الموضوع:
      2022
    • Collection:
      RD&E Research Repository (Royal Devon and Exeter NHS Foundation Trust)
    • نبذة مختصرة :
      BACKGROUND: Renal denervation has been shown to lower blood pressure in the presence of antihypertensive medications; however, long-term safety and efficacy data from randomised trials of renal denervation are lacking. In this pre-specified analysis of the SPYRAL HTN-ON MED study, we compared changes in blood pressure, antihypertensive drug use, and safety up to 36 months in renal denervation versus a sham control group. METHODS: This randomised, single-blind, sham-controlled trial enrolled patients from 25 clinical centres in the USA, Germany, Japan, the UK, Australia, Austria, and Greece, with uncontrolled hypertension and office systolic blood pressure between 150 mm Hg and 180 mm Hg and diastolic blood pressure of 90 mm Hg or higher. Eligible patients had to have 24-h ambulatory systolic blood pressure between 140 mm Hg and less than 170 mm Hg, while taking one to three antihypertensive drugs with stable doses for at least 6 weeks. Patients underwent renal angiography and were randomly assigned (1:1) to radiofrequency renal denervation or a sham control procedure. Patients and physicians were unmasked after 12-month follow-up and sham control patients could cross over after 12-month follow-up completion. The primary endpoint was the treatment difference in mean 24-h systolic blood pressure at 6 months between the renal denervation group and the sham control group. Statistical analyses were done on the intention-to-treat population. Long-term efficacy was assessed using ambulatory and office blood pressure measurements up to 36 months. Drug surveillance was used to assess medication use. Safety events were assessed up to 36 months. This trial is registered with ClinicalTrials.gov, NCT02439775; prospectively, an additional 260 patients are currently being randomly assigned as part of the SPYRAL HTN-ON MED Expansion trial. FINDINGS: Between July 22, 2015, and June 14, 2017, among 467 enrolled patients, 80 patients fulfilled the qualifying criteria and were randomly assigned to undergo renal denervation (n=38) ...
    • Relation:
      https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(22)00455-X; Lancet. 2022 Apr 9;399(10333):1401-1410. doi:10.1016/S0140-6736(22)00455-X. Epub 2022 Apr 4.; https://rde.dspace-express.com/handle/11287/622625; The Lancet
    • الرقم المعرف:
      10.1016/s0140-6736(22)00455-x
    • الدخول الالكتروني :
      https://doi.org/10.1016/s0140-6736(22)00455-x
      https://rde.dspace-express.com/handle/11287/622625
    • Rights:
      Copyright © 2022 Elsevier Ltd. All rights reserved. ; http://creativecommons.org/publicdomain/zero/1.0/
    • الرقم المعرف:
      edsbas.EFA93E74